Paula V. Marlton

199 Ipswich Rd
Woolloongabba, QLD 4102, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Journal: Internal medicine journal
Published: January 06, 2026

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Journal: Med (New York, N.Y.)
Published: April 16, 2025

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Journal: Blood
Published: January 27, 2025

Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statement.

Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statement.

Journal: Internal medicine journal
Published: December 05, 2024

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Journal: Blood advances
Published: November 18, 2024

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Journal: Internal medicine journal
Published: June 03, 2024

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.

Journal: Nature communications
Published: May 31, 2024

Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.

Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.

Journal: American journal of hematology
Published: November 13, 2023

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

Journal: Blood cancer journal
Published: October 22, 2023

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Journal: Blood advances
Published: July 28, 2023

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2023

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Journal: Blood advances
Published: June 06, 2023
Showing 1-12 of 60

Last Updated: 09/26/2026